Does Benicar (olmesartan) cause intestinal problems?
Benicar (olmesartan) has been linked to intestinal problems, most notably a sprue-like enteropathy that can cause chronic diarrhea and weight loss. This has been recognized in safety communications and prescribing information for olmesartan-containing products. The condition can develop after months to years of treatment in some patients. [1]
What intestinal symptoms should patients watch for?
Patients who develop these symptoms while taking Benicar should contact a clinician, especially if symptoms persist:
- Chronic diarrhea
- Weight loss
- Abdominal pain or bloating
This pattern is described as an olmesartan-associated sprue-like illness. [1]
What happens if someone stops Benicar?
When clinicians suspect an olmesartan-related intestinal reaction, the usual approach is to stop the drug and evaluate other causes of diarrhea. Improvement after discontinuation is often reported in described cases of this adverse reaction, which supports the drug–reaction link. [1]
How common is this, and who is at higher risk?
Serious olmesartan-associated intestinal effects are considered uncommon, but the risk is significant enough that regulators and manufacturers included it as a boxed warning/important safety information in labeling for olmesartan products. Specific risk factors are not clearly defined, and clinicians typically base decisions on symptoms, duration of therapy, and ruling out other causes of chronic diarrhea. [1]
Is this the same as “Benicar indigestion” or occasional stomach upset?
Occasional gastrointestinal side effects (like mild stomach discomfort) can occur with many medications, but the specific concern with olmesartan is the sprue-like enteropathy syndrome tied to chronic diarrhea and weight loss. If symptoms are persistent or worsening, it’s important to get medical advice rather than assuming it’s simple indigestion. [1]
Could there be other causes?
Chronic diarrhea has many causes (infections, inflammatory bowel disease, medication effects from other drugs, celiac disease, and more). Clinicians generally evaluate for common and serious alternatives when symptoms appear during treatment, especially if diarrhea continues despite stopping other potential triggers. [1]
Source
- DrugPatentWatch.com – Benicar (olmesartan medoxomil) information and related safety/patent context